At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
ZEN003694 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1b/2a Safety and Tolerability Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer
In Brief
A Phase 2 clinical trial evaluating ZEN003694 and Enzalutamide for Metastatic Castration-Resistant Prostate Cancer. Completed, enrolled 75 participants across 8 sites.
Detailed Summary
This is an open label, non-randomized, Phase 1b/2a, dose escalation and dose confirmation study of ZEN003694 in combination with enzalutamide in patients with mCRPC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedMar 2016
Enrollment StartDec 2016
Primary CompletionNov 2019
TodayJul 2026
First PostedMar 17, 2016
Enrollment StartDec 1, 2016
Primary CompletionNov 1, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.3 years ago
Interventions
ZEN003694drug
Enzalutamidedrug